CORDIS · PERSIST
Patients-centered SurvivorShIp care plan after Cancer treatments based on Big Data and Artificial Intelligence technologies
- Code
PERSIST- Programme
- H2020
- Call
SC1-DTH-01-2019- Status
- CLOSED
- Period
- 2020-01-01 – 2023-02-28
Official data · CORDIS · synced 2026-10-17 10:16 · official record
Participants
| Organisations | Role | Country | Grant |
|---|---|---|---|
| FUNDACION CENTRO TECNOLOXICO DE TELECOMUNICACIONS DE GALICIA | coordinator | ES | 680 480 € |
| SYMPTOMA GMBH | participant | AT | 692 125 € |
| DH HEALTHCARE PROVIDER SOFTWARE SPAIN SLU | participant | ES | 536 000 € |
| UNIVERZA V MARIBORU | participant | SI | 398 125 € |
| HAUTE ECOLE SPECIALISEE DE SUISSE OCCIDENTALE | participant | CH | 397 500 € |
| EMODA YAZILIM VE DANISMANLIK SANAYITICARET LIMITED SIRKETI | participant | TR | 356 875 € |
| DXC TECHNOLOGY SERVICIOS ESPANA SL | participant | ES | 315 775 € |
| CENTRE HOSPITALIER UNIVERSITAIRE DE LIEGE | participant | BE | 311 875 € |
| Univerzitetni klinicni center Maribor | participant | SI | 311 875 € |
| RUBYNANOMED LDA | participant | PT | 295 351 € |
| CYBERETHICS LAB SRL | participant | IT | 217 812 € |
| LATVIJAS UNIVERSITATE | participant | LV | 215 875 € |
| SERVIZO GALEGO DE SAUDE | participant | ES | 203 625 € |
| NATIONAL PATIENTS ORGANISATION | participant | BG | 131 812 € |
| ISOFT SANIDAD SA | third party | ES | 0 € |
| ENTERPRISE SOLUTIONS CONSULTORIA Y APLICACIONES | third party | ES | 0 € |
| FUNDACION PUBLICA GALEGA DE INVESTIGACION BIOMEDICA GALICIA SUR | third party | ES | 0 € |
Description
PERSIST aims at developing an open and interoperable ecosystem to improve the care of cancer survivors. The key results to be achieved by partners are: increased self-efficacy and satisfaction with care as well as reduced psychological stress for a better management of the consequences of the cancer treatment and the disease, resulting in an improvement in health and wellbeing and a faster integration into the labour market, where applicable, compared to usual care (KR1); increased effectiveness in cancer treatment and follow-up by providing prediction models from Big Data that will support decision-making and contribute to optimal treatment decisions with positive consequences in the QoL and the health status of survivors (KR2); and improved information and evidence to advance the efficacy of management, intervention and prevention policies/strategies in order to timely treat side effects and, if possible, avoid secondary diseases and fatal events. The long-term result will be to reduce the socio-economic burden related to cancer survivors’ care (KR3). The ecosystem proposed consists of a Big Data platform to be built on top of an open infrastructure from one of the partners and a mHealth application for patients. The main building blocks to be developed are a multimodal sensing network running on a smart phone that will collect relevant data regarding the wellbeing of the patient; predictive models from anonymised health data from thousands of breast and colorectal patients; and modules essential for the development of a decision support system, which will employ the predictive models mentioned. Furthermore, PERSIST will contribute to establish evidence on the use of liquid biopsy techniques to the follow-up of cancer patients treated with curative purposes. A pilot study involving 160 patients and 32 health care professionals will be decisive to establish a co-creation methodology ranging from the earlies phases of the project throughout its conclusion.
Official data · CORDIS · synced 2026-10-17 10:16 · official record · Licence: © European Union, CC BY 4.0 (Commission reuse policy).